Description
VX-11e inhibits ERK2 and exhibits anticancer activity. VX-11e also displays some inhibitory activity against aurora kinase A (AurA), glycogen synthase kinase 3 (GSK-3), CDK2, FLT3, ROCK1, and JNK3.
Product Info
| Cas No. | 896720-20-0 |
|---|---|
| Purity | ≥98% |
| Formula | C24H20Cl2FN5O2 |
| Formula Wt. | 500.35 |
| IUPAC Name | 4-[2-(2-chloro-4-fluoroanilino)-5-methylpyrimidin-4-yl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide |
| Synonym | ERK 11e, TCS ERK 11e |
| Solubility | DMSO 100 mg/mL (199.86 mM) Ethanol 16 mg/mL (31.97 mM) Water Insoluble |
| Appearance | Off-white Powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
References
Aronov AM, Tang Q, Martinez-Botella G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem. 2009 Oct 22;52(20):6362-8. PMID: 19827834.